{"task_id": "2bf09bbbe3949928", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 19/464)", "text": "ry flow rate\u2019\u2019\nJAMA 1995 273:4\nCOPD Exacerbation\n3\n\n--- Page 25 ---\nCLINICAL FEATURES (CONT\u2019D)\nSTEREOTYPES (not useful clinically)\n\u0002\nBLUE BLOATER (more chronic bronchitis)\ncough\nand sputum, hypoxemia, CO2 retention, pulmon\nary hypertension, right sided heart failure\n\u0002\nPINK PUFFER (more emphysema)\ncachexia, rela\ntively preserved blood gases, dyspnea even at rest\nPREDICTION RULE FOR OBSTRUCTIVE AIRWAY\nDISEASE\n\u0002\nAGE \u000545 YEARS\nLR+ 1.3\n\u0002\nSMOKING >40 PACK YEAR\nLR+ 8.3\n\u0002\nSELF-REPORTED HISTORY OF CHRONIC OBSTRUCTIVE AIR-\nWAY DISEASE\nLR+ 7.3\n\u0002\nMAXIMUM LARYNGEAL HEIGHT <4 CM [<1.6 IN.]\ndistance between the top of thyroid cartilage\nand suprasternal notch at end of expiration. LR+ 2.8\nJAMA 2000 283:14\nINVESTIGATIONS\nBASIC\n\u0002\nLABS\nCBCD, lytes, urea, Cr, troponin/CK, Ca, Mg,\nPO4\n\u0002\nMICROBIOLOGY\nsputum Gram stain/AFB/C&S/\nfungal\n\u0002\nIMAGING\nCXR\n\u0002 ECG\nleft atrial enlargement, atrial fibrillation,\nsinus tachycardia\n\u0002\nSPIROMETRY/PFT\nFEV1/FVC <0.7, partially rever\nsible. Severity based on FEV1\n\u0002 ABG\nif acute respiratory distress\nSPECIAL\n\u0002 BNP\nif suspect HF\n\u0002 D dimer\nif suspect PE\n\u0002\nECHOCARDIOGRAM\nPROGNOSTIC ISSUES\nPROGNOSIS OF PATIENTS WITH ACUTE EXACERBA\nTION OF COPD\nin hospital mortality 5 10%\nGOLD CLASSIFICATION 2007\nall have FEV1/FVC\n<0.7\n\u0002\nSTAGE I (MILD)\nFEV1 \u000580% predicted\n\u0002\nSTAGE II (MODERATE)\nFEV1 50 79% predicted\n\u0002\nSTAGE III (SEVERE)\nFEV1 30 49% predicted\n\u0002\nSTAGE IV (VERY SEVERE)\nFEV1 <30% predicted, or\n<50% predicted + cor pulmonale\nBODE INDEX\n\u0002 BMI\n0= >21, 1= \u000621\n\u0002\nOBSTRUCTION (post bronchodilator FEV1)\n0 \u000565%\npredicted, 1=50 64%, 2=36 49%, 3= \u000635%\n\u0002\nDISTANCE\nWALKED\nIN\n6\nMIN\n0=\u0005350\nm,\n1=250 349 m, 2=150 249 m, 3= \u0006149 m\n\u0002\nEXERCISE MMRC DYSPNEA\n0=0 1, 1=2, 2=3, 3=4\n\u0002\nSCORING\nhazard ratio for death from any cause\nper one point increase in BODE score is 1.34\nNEJM 2004 350:10\nACUTE MANAGEMENT\nABC\nO2 to keep sat >90%, or 88 92% if CO2 retai\nner, IV\nBRONCHODILATORS\nsalbutamol 2.5 5 mg NEB\nq4h ATC + q1h PRN and ipratropium 0.25 0.5 mg\nNEB q4h. Puffers preferable for acute management if\nproper technique used\nSTEROIDS\nprednisone 40 60 mg PO daily \u000314\ndays (tapering dose not necessary in all cases) or\nmethylprednisolone\n60 125\nmg\nIV\ndaily\n(inpatient)\nANTIBIOTICS\ngive if any two of the following\ncriteria are met: \" sputum purulence, \" dyspnea or\n\" sputum volume. Other considerations include the\nneed for non invasive mechanical ventilation and\n\u2018\u2018at risk\u2019\u2019 for poor outcome (substantial comorbi\ndities,\nsevere\nCOPD,\nfrequent\nexacerbations\n>3/year, recent antibiotics within 3 months);\nchoices depend on clinical circumstance (levoflox\nawcin 500 mg PO daily \u00037 days, doxycycline 100 mg\nPO BID \u00037 10 days, amoxicillin 500 mg PO BID \u00037\ndays, cefuroxime 250 500 mg PO BID \u000310 days, or\nazithromycin 500 mg PO \u00031 day then 250 mg PO\ndaily \u00034 days)\nMECHANICAL VENTILATION\nBIPAP, intubation\nOTHERS\nDVT prophylaxis (heparin 5000 U SC BID),\nphysiotherapy\nNEJM 2002 346:13\nLONG TERM MANAGEMENT\nEDUCATION\nsmoking cessation (see p. 418). Dis\nease specific\nself management\nprogram.\nPuffer\ntechnique education and review\nVACCINATIONS\ninfluenza vaccine annually and\npneumococcal vaccine booster at 5 years\nREHABILITATION\nexercise\ntraining\n(increases\nquality of life and exercise tolerance)\nFIRST LINE\nshort acting b2 agonist or short act\ning anticholinergic on an as needed basis\nSECOND LINE\nlong acting b2 agonist or long\nacting anticholinergic (tiotropium 1 puff [18 mg/\npuff] INH daily) plus short acting b2 agonist PRN.\nConsider early initiation of long acting agents if\nrequiring regular PRN short acting agents as long\nacting agents are superior\nTHIRD LINE\nlong acting b2 agonist plus long\nacting anticholinergic, with short acting b2 agonist\nPRN\nFOURTH LINE\nlong acting anticholinergic plus\nlong acting\nb2 agonist/inhaled\ncorticosteroid\ncombination (e.g. Advair, Symbicort). No role for\ninhaled corticosteroid alone in COPD\nFIFTH LINE\nfourth line plus theophylline 400 mg\nPO daily \u00033 days, then 400 600 mg PO daily, ther\napeutic level 10 20 mg/mL\nSIXTH LINE\nfifth line plus home O2\n4\nCOPD Exacerbation", "text_length": 4008, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 19/464)", "type": "chunk", "chunk_index": 18, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.257887", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.258613", "status": "complete", "chunks_added": 3}